A Food and Drug Administration advisory committee is set to meet

Feb. 16 to discuss CEA-Scan, a monoclonal antibody imaging agent

for colorectal cancer developed by Immunomedics. Immunomedics,

of Morris Plains, NJ, has been working with the FDA on the agent's

product license application (PLA) since the agency said the PLA

was not approvable in 1994 (SCAN 6/1/94).

A Food and Drug Administration advisory committee is set to meetFeb. 16 to discuss CEA-Scan, a monoclonal antibody imaging agentfor colorectal cancer developed by Immunomedics. Immunomedics,of Morris Plains, NJ, has been working with the FDA on the

FDA panel to discuss Immunomedics agent